Revised SPC: Darzalex (daratumumab) 1,800 mg solution for injection
Sepsis was added to SPC as a common adverse reaction in multiple myeloma patients treated with intravenous or subcutaneous daratumumab.
Source:
electronic Medicines compendium
Sepsis was added to SPC as a common adverse reaction in multiple myeloma patients treated with intravenous or subcutaneous daratumumab.
electronic Medicines compendium